Overview

Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan. Despite decades' intensive studies, surgery and local-regional chemo-embolization, radio-frequency ablation or radiation therapy remain the mainstay of HCC treatments.

Phase:

PHASE1

Details

Lead Sponsor:

China Medical University Hospital

Treatments:

alectinib
Nivolumab